AKT1 and breast cancer: Within comprehensive molecular profiling studies of breast cancer tissue, the AKT1E17K mutation was identified as a probable oncogenic driver in patients, indicating that the inhibition of AKT1 presents a novel and specific drug target in this disease [5,6].